Insider Trading Alert - HIL, PCRX And LMAT Traded By Insiders

Yesterday, Jan. 14, 2016, 33 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $925.00 to $5,000,000.00.

Highlighted Stocks Traded by Insiders:

Hill International (HIL) - FREE Research Report

Richter Irvin E, who is Director at Hill International, sold 20,124 shares at $3.38 on Jan. 14, 2016. Following this transaction, the Director owned 5.0 million shares meaning that the stake was reduced by 0.4% with the 20,124-share transaction.

The shares most recently traded at $3.12, down $0.26, or 8.4% since the insider transaction. Historical insider transactions for Hill International go as follows:

  • 4-Week # shares sold: 78,500
  • 12-Week # shares sold: 125,000
  • 24-Week # shares sold: 184,639

The average volume for Hill International has been 140,300 shares per day over the past 30 days. Hill International has a market cap of $163.4 million and is part of the services sector and diversified services industry. Shares are down 18.04% year-to-date as of the close of trading on Thursday.

Hill International, Inc. provides program management, project management, construction management, construction claims, and other consulting services primarily for the buildings, transportation, environmental, energy, and industrial markets worldwide. Currently, there are 2 analysts who rate Hill International a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HIL - FREE

TheStreet Quant Ratings rates Hill International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full Hill International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pacira Pharmaceuticals (PCRX) - FREE Research Report

Longenecker John P Phd, who is Director at Pacira Pharmaceuticals, bought 300 shares at $66.55 on Jan. 14, 2016. Following this transaction, the Director owned 2,300 shares meaning that the stake was boosted by 15% with the 300-share transaction.

Jones James B, who is SVP & Chief Medical Officer at Pacira Pharmaceuticals, bought 1,000 shares at $66.00 on Jan. 14, 2016. Following this transaction, the SVP & Chief Medical Officer owned 1,000 shares meaning that the stake was boosted by 100% with the 1,000-share transaction.

The shares most recently traded at $64.17, down $1.83, or 2.85% since the insider transaction. Historical insider transactions for Pacira Pharmaceuticals go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 22,746

The average volume for Pacira Pharmaceuticals has been 908,400 shares per day over the past 30 days. Pacira Pharmaceuticals has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are down 14.7% year-to-date as of the close of trading on Thursday.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has a P/E ratio of 219.2. Currently, there are 6 analysts who rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCRX - FREE

TheStreet Quant Ratings rates Pacira Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full Pacira Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LeMaitre Vascular (LMAT) - FREE Research Report

Roberts David B, who is President and Director at LeMaitre Vascular, sold 12,867 shares at $15.85 on Jan. 14, 2016. Following this transaction, the President and Director owned 127,739 shares meaning that the stake was reduced by 9.15% with the 12,867-share transaction.

The shares most recently traded at $15.14, down $0.71, or 4.72% since the insider transaction. Historical insider transactions for LeMaitre Vascular go as follows:

  • 4-Week # shares sold: 30,233
  • 12-Week # shares sold: 219,319
  • 24-Week # shares sold: 465,267

The average volume for LeMaitre Vascular has been 161,300 shares per day over the past 30 days. LeMaitre Vascular has a market cap of $287.9 million and is part of the health care sector and health services industry. Shares are down 7.88% year-to-date as of the close of trading on Thursday.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease worldwide. The stock currently has a dividend yield of 1.01%. The company has a P/E ratio of 39.7. Currently, there are 6 analysts who rate LeMaitre Vascular a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LMAT - FREE

TheStreet Quant Ratings rates LeMaitre Vascular as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full LeMaitre Vascular Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Fiat Slides After CEO Sergio Marchionne Leaves Automaker Amid Failing Health

Fiat Slides After CEO Sergio Marchionne Leaves Automaker Amid Failing Health

U.S. Dollar Steadies as Mnuchin Tames Currency War Concerns - For Now

U.S. Dollar Steadies as Mnuchin Tames Currency War Concerns - For Now

Google, Fiat Chrysler, Tesla and Papa John's - 5 Things You Must Know

Google, Fiat Chrysler, Tesla and Papa John's - 5 Things You Must Know

Stocks Slide, Dollar Weakens as Trade, Trump and Tariffs Hold Down Sentiment

Stocks Slide, Dollar Weakens as Trade, Trump and Tariffs Hold Down Sentiment

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS